top of page
lungs 4.png
png-transparent-teva-pharmaceutical-industries-pharmaceutical-industry-teva-pharmaceutical

FLAIR Study

The FLAIR Study is evaluating the effectiveness and safety of a combination of 2 commercially approved drugs, fluticasone (Fp) and albuterol (ABS), in a single inhaler compared to albuterol (ABS) alone for asthma attacks in adults, adolescents, and children with asthma.
The study will determine if using the study combination will reduce the occurrence of asthma episodes ("attacks") that require systemic corticosteroids or hospitalizations for treatment.

lung.png
White Structure
inhaler.png

Who Can Join

​To participate in this study, you must:

  • Be 4 years of age or older

  • Be diagnosed with asthma for at least 1 year

  • Have had 1 or more severe asthma attacks in the past 12 months

​

There are also other requirements that will determine who can participate. A doctor will determine if you are medically eligible to take part in this study.
 

Important Information

  • During the study, participants will continue taking their usual asthma maintenance medication

  • Participants will be in the study for at least 6 months

  • The investigational study drug and study procedures are provided at no charge

  • Travel and study-related costs may be reimbursed

  • There is no placebo arm in this study; participants will receive either the study drug combination or ABS 

  • The study enrollment is expected to last until approximately the third quarter of 2025

Interested in Participating?

Schedule a Pre-Screen Appointment:

or

Complete the Form Below

bottom of page